Compare Ford Motor Company (F) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Incyte Corporation — how do they compare? Ford Motor Company trades at $14.13 (market cap $56.50B), while Incyte Corporation trades at $116.04 (market cap $22.99B). The key difference: Ford Motor Company is far larger — about 2.5× Incyte Corporation's market cap, and Ford Motor Company pays a 4.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| F | INCY | |
|---|---|---|
Market Cap | $56.50B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $118.52 |
52-Week Low | $10.82 | $67.38 |
Enterprise Value | $185.53B | $19.01B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $14.09, up 1.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.00. Recent earnings show volatility with Q1 2026 beating expectations but Q4 2025 missing, while revenue grew to $187.27 billion in 2025. The company maintains strong cash flow from operations at $21.28 billion and announced a $0.15 dividend for H1 2026, though net income was negative at -$8.18 billion due to high costs.
Ford's outlook is mixed, with opportunities from EV expansion and labor stability, but risks include profit margin pressure and rising debt. Analysts are cautiously optimistic with 34% buy ratings, yet investors should weigh competitive threats and macroeconomic headwinds against the stock's low P/E of 11.84 and dividend yield.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
